Intracerebral haemorrhage in patients taking different types of oral anticoagulants : a pooled individual patient data analysis from two national stroke registries
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: We investigated outcomes in patients with intracerebral haemorrhage (ICH) according to prior anticoagulation treatment with Vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) or no anticoagulation.
METHODS: This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway (2013-2019). We included all consecutive patients with ICH from both registries. The main outcomes were favourable functional outcome (modified Rankin Scale 0-2) and mortality at 3 months.
RESULTS: Among 11 349 patients with ICH (mean age 73.6 years; 47.6% women), 1491 (13.1%) were taking VKAs and 1205 (10.6%) DOACs (95.2% factor Xa inhibitors). The median percentage of patients on prior anticoagulation was 23.7 (IQR 22.6-25.1) with VKAs decreasing (from 18.3% to 7.6%) and DOACs increasing (from 3.0% to 18.0%) over time. Prior VKA therapy (n=209 (22.3%); adjusted ORs (aOR), 0.64; 95% CI, 0.49 to 0.84) and prior DOAC therapy (n=184 (25.7%); aOR, 0.64; 95% CI, 0.47 to 0.87) were independently associated with lower odds of favourable outcome compared with patients without anticoagulation (n=2037 (38.8%)). Prior VKA therapy (n=720 (49.4%); aOR, 1.71; 95% CI, 1.41 to 2.08) and prior DOAC therapy (n=460 (39.7%); aOR, 1.28; 95% CI, 1.02 to 1.60) were independently associated with higher odds of mortality compared with patients without anticoagulation (n=2512 (30.2%)).
CONCLUSIONS: The spectrum of anticoagulation-associated ICH changed over time. Compared with patients without prior anticoagulation, prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3 months. Specific reversal agents unavailable during the study period might improve outcomes of DOAC-associated ICH in the future.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Stroke and vascular neurology - (2024) vom: 08. Feb. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 09.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1136/svn-2023-002813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368258572 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368258572 | ||
| 003 | DE-627 | ||
| 005 | 20240210233433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/svn-2023-002813 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM368258572 | ||
| 035 | |a (NLM)38336370 | ||
| 035 | |a (PII)svn-2023-002813 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Siepen, Bernhard M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intracerebral haemorrhage in patients taking different types of oral anticoagulants |b a pooled individual patient data analysis from two national stroke registries |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: We investigated outcomes in patients with intracerebral haemorrhage (ICH) according to prior anticoagulation treatment with Vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) or no anticoagulation | ||
| 520 | |a METHODS: This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway (2013-2019). We included all consecutive patients with ICH from both registries. The main outcomes were favourable functional outcome (modified Rankin Scale 0-2) and mortality at 3 months | ||
| 520 | |a RESULTS: Among 11 349 patients with ICH (mean age 73.6 years; 47.6% women), 1491 (13.1%) were taking VKAs and 1205 (10.6%) DOACs (95.2% factor Xa inhibitors). The median percentage of patients on prior anticoagulation was 23.7 (IQR 22.6-25.1) with VKAs decreasing (from 18.3% to 7.6%) and DOACs increasing (from 3.0% to 18.0%) over time. Prior VKA therapy (n=209 (22.3%); adjusted ORs (aOR), 0.64; 95% CI, 0.49 to 0.84) and prior DOAC therapy (n=184 (25.7%); aOR, 0.64; 95% CI, 0.47 to 0.87) were independently associated with lower odds of favourable outcome compared with patients without anticoagulation (n=2037 (38.8%)). Prior VKA therapy (n=720 (49.4%); aOR, 1.71; 95% CI, 1.41 to 2.08) and prior DOAC therapy (n=460 (39.7%); aOR, 1.28; 95% CI, 1.02 to 1.60) were independently associated with higher odds of mortality compared with patients without anticoagulation (n=2512 (30.2%)) | ||
| 520 | |a CONCLUSIONS: The spectrum of anticoagulation-associated ICH changed over time. Compared with patients without prior anticoagulation, prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3 months. Specific reversal agents unavailable during the study period might improve outcomes of DOAC-associated ICH in the future | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a Hemorrhage | |
| 650 | 4 | |a Stroke | |
| 700 | 1 | |a Forfang, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Branca, Mattia |e verfasserin |4 aut | |
| 700 | 1 | |a Drop, Boudewijn |e verfasserin |4 aut | |
| 700 | 1 | |a Mueller, Madlaine |e verfasserin |4 aut | |
| 700 | 1 | |a Goeldlin, Martina B |e verfasserin |4 aut | |
| 700 | 1 | |a Katan, Mira |e verfasserin |4 aut | |
| 700 | 1 | |a Michel, Patrik |e verfasserin |4 aut | |
| 700 | 1 | |a Cereda, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Medlin, Friedrich |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Renaud, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Niederhauser, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Carrera, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Kahles, Timo |e verfasserin |4 aut | |
| 700 | 1 | |a Kägi, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Bolognese, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Salmen, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Mono, Marie-Luise |e verfasserin |4 aut | |
| 700 | 1 | |a Polymeris, Alexandros A |e verfasserin |4 aut | |
| 700 | 1 | |a Wegener, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Z'Graggen, Werner |e verfasserin |4 aut | |
| 700 | 1 | |a Kaesmacher, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Schaerer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Rodic, Biljana |e verfasserin |4 aut | |
| 700 | 1 | |a Kristoffersen, Espen Saxhaug |e verfasserin |4 aut | |
| 700 | 1 | |a Larsen, Kristin T |e verfasserin |4 aut | |
| 700 | 1 | |a Wyller, Torgeir Bruun |e verfasserin |4 aut | |
| 700 | 1 | |a Volbers, Bastian |e verfasserin |4 aut | |
| 700 | 1 | |a Meinel, Thomas R |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Marcel |e verfasserin |4 aut | |
| 700 | 1 | |a Engelter, Stefan T |e verfasserin |4 aut | |
| 700 | 1 | |a Bonati, Leo H |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Urs |e verfasserin |4 aut | |
| 700 | 1 | |a Rønning, Ole Morten |e verfasserin |4 aut | |
| 700 | 1 | |a Seiffge, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke and vascular neurology |d 2016 |g (2024) vom: 08. Feb. |w (DE-627)NLM263633950 |x 2059-8696 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:08 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/svn-2023-002813 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 08 |c 02 | ||